Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Anthony Boutros El-Khoueiry, MD

    TitleAssociate Professor of Clinical Medicine
    SchoolKeck School of Medicine of USC
    DepartmentMedicine
    AddressNOR 3451
    Health Sciences Campus
    Los Angeles California 90089-9173
    Phone+1 323 865 3900
    vCardDownload vCard
      Other Positions
      TitleNorris Cancer Center Ciso Chair


      Collapse Overview 
      Collapse Overview
      Anthony El-Khoueiry, MD, is an assistant professor of clinical medicine at the Keck School of Medicine of USC and director of clinical translation at the Southern California Clinical and Translational Science Institute (SC CTSI). He has extensive experience in clinical and translational research through his roles as medical director of the Clinical Investigations Support Office and director of the phase I drug development program at the USC Norris Comprehensive Cancer Center. He is the recipient of the National Cancer Institute Cancer Investigator Team Leadership Award in 2011.

      Dr. El-Khoueiry has established a national reputation in clinical research-related hepatobiliary (liver, gall bladder and bile duct) and pancreatic cancers. He is a member of the National Cancer Institute Hepatobiliary Cancers Task Force and chair of the Southwest Oncology Group hepatobiliary cancers subcommittee. In addition, he is the principal investigator of several phase I, including first-in-human, clinical trials aimed at developing novel therapies for solid tumors. Dr. El-Khoueiry works with several basic scientists at USC on joint translational projects designed to identify molecular predictors of outcome and survival for patients with advanced gastrointestinal cancers.

      Dr. El-Khoueiry completed his medical degree, residency in internal medicine and fellowship in hematology and oncology at USC. He unravels scientific and non-scientific mysteries in four languages: English, Arabic, French and Spanish.


      Collapse Biography 
      Collapse Clinical Trials
      Collapse Awards and Honors
      USC1998Dean's Scholar
      Division of Hematology2003Researcher of the Year
      Southwest Oncology Group2004Young Investigator Training Award
      National Cancer Institute 2011  - 2012Clinical Investigator Team Leadership Award
      University of California, IrvineGolden Key National Honor Society

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat; a phase 2 consortium/stand Up 2 cancer study. Oncotarget. 2017 Feb 05. PMID: 28186961.
        View in: PubMed
      2. Adjei AA, Richards DA, El-Khoueiry A, Braiteh F, Becerra CH, Stephenson JJ, Hezel AF, Sherman M, Garbo L, Leffingwell DP, Iverson C, Miner JN, Shen Z, Yeh LT, Gunawan S, Wilson DM, Manhard KJ, Rajagopalan P, Krissel H, Clendeninn NJ. A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer. Clin Cancer Res. 2016 May 15; 22(10):2368-76. PMID: 26644411.
        View in: PubMed
      3. Kuang Y, El-Khoueiry A, Taverna P, Ljungman M, Neamati N. Guadecitabine (SGI-110) priming sensitizes hepatocellular carcinoma cells to oxaliplatin. Mol Oncol. 2015 Nov; 9(9):1799-814. PMID: 26160429.
        View in: PubMed
      4. Ben-Josef E, Guthrie KA, El-Khoueiry A, Corless CL, Zalupski MM, Lowy AM, Thomas CR, Alberts SR, Dawson LA, Micetich KC, Thomas MB, Siegel AB, Blanke CD. SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma. J Clin Oncol. 2015 Aug 20; 33(24):2617-22. PMID: 25964250.
        View in: PubMed
      5. Siegel AB, El-Khoueiry A, Finn RS, Guthrie KA, Goyal A, Venook AP, Blanke CD, Verna EC, Dove L, Emond J, Kato T, Samstein B, Busuttil R, Remotti H, Coffey A, Brown RS. Phase I trial of sorafenib following liver transplantation in patients with high-risk hepatocellular carcinoma. Liver Cancer. 2015 Mar; 4(2):115-25. PMID: 26020033.
        View in: PubMed
      6. Newman EM, Morgan RJ, Kummar S, Beumer JH, Blanchard MS, Ruel C, El-Khoueiry A, Carroll MI, Hou JM, Li C, Lenz HJ, Eiseman JL, Doroshow JH. A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine. Cancer Chemother Pharmacol. 2015 Mar; 75(3):537-46. PMID: 25567350.
        View in: PubMed
      7. Bohanes P, Yang D, Loupakis F, LaBonte MJ, Gerger A, Ning Y, Lenz C, Lenz F, Wakatsuki T, Zhang W, Benhaim L, El-Khoueiry A, El-Khoueiry R, Lenz HJ. Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer. Pharmacogenomics J. 2015 Jun; 15(3):226-34. PMID: 25487679.
        View in: PubMed
      8. Wagner AJ, Messersmith WA, Shaik MN, Li S, Zheng X, McLachlan KR, Cesari R, Courtney R, Levin WJ, El-Khoueiry A. A Phase I Study of PF-04449913, an Oral Hedgehog Inhibitor, in Patients with Advanced Solid Tumors. Clin Cancer Res. 2015 Mar 1; 21(5):1044-51. PMID: 25388167.
        View in: PubMed
      9. Piatek CI, Raja GL, Ji L, Gitlitz BJ, Dorff TB, Quinn DI, Hu J, El-Khoueiry A, Pham HQ, Roman L, Garcia AA. Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. Cancer Chemother Pharmacol. 2014 Dec; 74(6):1227-34. PMID: 25374407.
        View in: PubMed
      10. Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry A, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM. Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. Br J Cancer. 2014 Dec 9; 111(12):2268-74. PMID: 25349975.
        View in: PubMed
      11. Knox JJ, Qin R, Strosberg JR, Tan B, Kaubisch A, El-Khoueiry A, Bekaii-Saab TS, Rousey SR, Chen HX, Erlichman C. A phase II trial of bevacizumab plus temsirolimus in patients with advanced hepatocellular carcinoma. Invest New Drugs. 2015 Feb; 33(1):241-6. PMID: 25318437.
        View in: PubMed
      12. Yang D, Hanna DL, Usher J, LoCoco J, Chaudhari P, Lenz HJ, Setiawan VW, El-Khoueiry A. Impact of sex on the survival of patients with hepatocellular carcinoma: A Surveillance, Epidemiology, and End Results analysis. Cancer. 2014 Dec 1; 120(23):3707-16. PMID: 25081299.
        View in: PubMed
      13. El-Khoueiry A, Rankin C, Siegel AB, Iqbal S, Gong IY, Micetich KC, Kayaleh OR, Lenz HJ, Blanke CD. S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma. Br J Cancer. 2014 Feb 18; 110(4):882-7. PMID: 24423918.
        View in: PubMed
      14. El-Khoueiry A, Posey JA, Castillo Ferrando JR, Krishnamurthi SS, Syed S, Kollia G, Walters I, Fischer BS, Masson E. The effects of liver impairment on the pharmacokinetics of brivanib, a dual inhibitor of fibroblast growth factor receptor and vascular endothelial growth factor receptor tyrosine kinases. Cancer Chemother Pharmacol. 2013 Jul; 72(1):53-64. PMID: 23719718.
        View in: PubMed
      15. Zhu AX, Gold PJ, El-Khoueiry A, Abrams TA, Morikawa H, Ohishi N, Ohtomo T, Philip PA. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013 Feb 15; 19(4):920-8. PMID: 23362325.
        View in: PubMed
      16. Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, Ladner RD. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer. Invest New Drugs. 2013 Aug; 31(4):845-57. PMID: 23299388.
        View in: PubMed
      17. Pohl A, El-Khoueiry A, Yang D, Zhang W, Lurje G, Ning Y, Winder T, Hu-Lieskoven S, Iqbal S, Danenberg KD, Kahn M, Teo JL, Shriki J, Stebbing J, Lenz HJ. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy. Pharmacogenomics J. 2013 Apr; 13(2):173-80. PMID: 22231565.
        View in: PubMed
      18. Labonte MJ, Wilson PM, Yang D, Zhang W, Ladner RD, Ning Y, Gerger A, Bohanes PO, Benhaim L, El-Khoueiry R, El-Khoueiry A, Lenz HJ. The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jun; 23(6):1455-64. PMID: 21989330.
        View in: PubMed
      19. Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, LaBonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, El-Khoueiry A, Kahn M, Lenz HJ. Common cancer stem cell gene variants predict colon cancer recurrence. Clin Cancer Res. 2011 Nov 1; 17(21):6934-43. PMID: 21918173.
        View in: PubMed
      20. Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ. Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Clin Cancer Res. 2011 Sep 1; 17(17):5783-92. PMID: 21791631.
        View in: PubMed
      21. El-Khoueiry A, Rankin CJ, Ben-Josef E, Lenz HJ, Gold PJ, Hamilton RD, Govindarajan R, Eng C, Blanke CD. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012 Aug; 30(4):1646-51. PMID: 21748296.
        View in: PubMed
      22. Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O, Velasquez L, Hayes W, Feltquate D, Syed S, Ford S, Kollia G, Galbraith S, Nuyten DS. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer. 2011 Jun 28; 105(1):44-52. PMID: 21629245.
        View in: PubMed
      23. Iqbal S, Rankin C, Lenz HJ, Gold PJ, Ahmad SA, El-Khoueiry A, Messino MJ, Holcombe RF, Blanke CD. A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202. Cancer Chemother Pharmacol. 2011 Dec; 68(6):1595-602. PMID: 21556747.
        View in: PubMed
      24. LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ, Ladner RD. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models. Cancer Res. 2011 May 15; 71(10):3635-48. PMID: 21464044.
        View in: PubMed
      25. El-Khoueiry A, Ramanathan RK, Yang DY, Zhang W, Shibata S, Wright JJ, Gandara D, Lenz HJ. A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. Invest New Drugs. 2012 Jun; 30(3):1175-83. PMID: 21424698.
        View in: PubMed
      26. Iqbal S, Tsao-Wei DD, Quinn DI, Gitlitz BJ, Groshen S, Aparicio A, Lenz HJ, El-Khoueiry A, Pinski J, Garcia AA. Phase I clinical trial of pegylated liposomal Doxorubicin and docetaxel in patients with advanced solid tumors. Am J Clin Oncol. 2011 Feb; 34(1):27-31. PMID: 20142723.
        View in: PubMed
      27. Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol. 2010 Apr; 65(5):979-88. PMID: 20062993.
        View in: PubMed
      28. Zhu AX, El-Khoueiry A, Llovet JM. Accomplishments in 2008 in the management of hepatobiliary cancers. Gastrointest Cancer Res. 2009 Sep; 3(5 Supplement 2):S28-36. PMID: 20011562.
        View in: PubMed
      29. Lurje G, Husain H, Power DG, Yang D, Groshen S, Pohl A, Zhang W, Ning Y, Manegold PC, El-Khoueiry A, Iqbal S, Tang LH, Shah MA, Lenz HJ. Genetic variations in angiogenesis pathway genes associated with clinical outcome in localized gastric adenocarcinoma. Ann Oncol. 2010 Jan; 21(1):78-86. PMID: 19622587.
        View in: PubMed
      30. Etzioni DA, El-Khoueiry A, Beart RW. Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer. 2008 Dec 15; 113(12):3279-89. PMID: 18951522.
        View in: PubMed
      31. Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab. Clin Cancer Res. 2008 Dec 1; 14(23):7884-95. PMID: 19047118.
        View in: PubMed
      32. Press OA, Zhang W, Gordon MA, Yang D, Lurje G, Iqbal S, El-Khoueiry A, Lenz HJ. Gender-related survival differences associated with EGFR polymorphisms in metastatic colon cancer. Cancer Res. 2008 Apr 15; 68(8):3037-42. PMID: 18413774.
        View in: PubMed
      33. Lurje G, Zhang W, Yang D, Groshen S, Hendifar AE, Husain H, Nagashima F, Chang HM, Fazzone W, Ladner RD, Pohl A, Ning Y, Iqbal S, El-Khoueiry A, Lenz HJ. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics. 2008 Feb; 18(2):161-8. PMID: 18192902.
        View in: PubMed
      34. Azuma M, Shi M, Danenberg KD, Gardner H, Barrett C, Jacques CJ, Sherod A, Iqbal S, El-Khoueiry A, Yang D, Zhang W, Danenberg PV, Lenz HJ. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients. Pharmacogenomics. 2007 Dec; 8(12):1705-13. PMID: 18086000.
        View in: PubMed
      35. Zhang W, Press OA, Haiman CA, Yang DY, Gordon MA, Fazzone W, El-Khoueiry A, Iqbal S, Sherrod AE, Lurje G, Lenz HJ. Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer. J Clin Oncol. 2007 Aug 20; 25(24):3726-31. PMID: 17704422.
        View in: PubMed
      36. Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2006 Nov; 6(4):305-11. PMID: 17241515.
        View in: PubMed
      37. Govindarajan R, Adusumilli J, Baxter DL, El-Khoueiry A, Harik SI. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol. 2006 Oct 1; 24(28):e48. PMID: 17008686.
        View in: PubMed
      38. Azuma M, Danenberg KD, Iqbal S, El-Khoueiry A, Zhang W, Yang D, Koizumi W, Saigenji K, Danenberg PV, Lenz HJ. Epidermal growth factor receptor and epidermal growth factor receptor variant III gene expression in metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Sep; 6(3):214-8. PMID: 17026791.
        View in: PubMed
      39. Schneider S, Park DJ, Yang D, El-Khoueiry A, Sherrod A, Groshen S, Streeter O, Iqbal S, Danenberg KD, Lenz HJ. Gene expression in tumor-adjacent normal tissue is associated with recurrence in patients with rectal cancer treated with adjuvant chemoradiation. Pharmacogenet Genomics. 2006 Aug; 16(8):555-63. PMID: 16847424.
        View in: PubMed
      40. El-Khoueiry A, Lenz HJ. Should continuous infusion 5-fluorouracil become the standard of care in the USA as it is in Europe? Cancer Invest. 2006 Feb; 24(1):50-5. PMID: 16466993.
        View in: PubMed
      41. Challita PM, Skelton D, el-Khoueiry A, Yu XJ, Weinberg K, Kohn DB. Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol. 1995 Feb; 69(2):748-55. PMID: 7815539.
        View in: PubMed